NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of...
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients...
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to...
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered...
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.